Starboard Value disclosed its newest activist target on Friday, and it apparently took investors by surprise.
The New York hedge fund firm said it owned 9.8 percent of Depomed, a pharmaceutical company that specializes in neurology-related products. The stock — which has a roughly $1 billion market value — surged 13 percent, to close at $16.95.
